VB Spine Launches in Australia and New Zealand
VB Spine continues to have exclusive access to Stryker's Mako Spine and the Copilot automatic depth stop feature. This strategic partnership creates a strong foundation for VB Spine's continued growth, providing surgeons greater precision and improving patient outcomes.
'From the start, our vision has been simple: put patients first and innovate boldly,' said Marc Viscogliosi, co-CEO of VB Spine, speaking for his brothers and fellow co-CEOs Anthony and John Viscogliosi. 'Today we take that vision global. By combining the passion of our family-run culture with LifeHealthcare's best-in-class surgeon support, we're opening a new chapter in spine care defined by access, outcomes, and possibility.'
LifeHealthcare, already the long-standing distributor for these products, will continue as the exclusive partner, providing uninterrupted product availability and clinical support for surgeons and their patients throughout Australia and New Zealand.
Paul Petherbridge, CEO of LifeHealthcare, said, 'We are pleased to announce our long-term collaboration with VB Spine. LifeHealthcare has represented this portfolio since 2010, providing clinicians and patients in Australia and New Zealand with reliable access to spinal instrumentation and implants through our experienced team. Our partnership with VB Spine aligns with our mission for Spine in ANZ: 'What matters to you drives us.' We look forward to working with the Viscogliosi brothers and the VB Spine team to offer innovative solutions and valuable education to our clinicians.'
Transition highlights
All current spinal implant SKUs remain available through LifeHealthcare with no service interruption.
Surgeons and hospitals will continue to work with their local LifeHealthcare representatives.
VB Spine plans to attend Deformity Down Under (DDU) in Brisbane, which began as a surgeon-led initiative to foster collaboration, share knowledge, and improve outcomes in spine surgery.
Forward-looking statements
Certain statements in this release are forward-looking and are based on current expectations, forecasts, and assumptions. Actual results may differ materially due to regulatory, commercial, and operational risks. VB Spine disclaims any obligation to update forward-looking statements except as required by law.
Transaction financing
Viscogliosi Brothers, LLC and Viscogliosi Brothers Watermark Holdings LLC are equity investors in VB Spine.
About VB Spine
VB Spine LLC is the largest privately held spine company and among the largest family-owned medical technology companies in the world. With a comprehensive product portfolio and a large and growing global distribution network, VB Spine delivers specialized solutions that address critical needs in spine surgery and enhance patient outcomes. Focused on people, partnerships and operational excellence, VB Spine ensures healthcare professionals have access to the tools and resources needed to provide the highest standard of care. VB Spine is owned and led by the Viscogliosi Brothers. For more information on VB Spine, please visit www.vbspineco.com.
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
About LifeHealthcare Distribution Pty Ltd (Australia) and LifeHealthcare Ltd (New Zealand)
LifeHealthcare, an EBOS MedTech company, is committed to providing patients in Australia and New Zealand with access to world-class medical devices and technology. Our goal is to ensure the long-term economic sustainability of the healthcare system. We offer a diverse range of products across various channels for surgical intervention, including but not limited to therapeutic areas such as Spine and Enabling Technology, Orthopaedics (Reconstruction, Extremities, and Regenerative Medicine), Plastics and Reconstructive Surgery, Neurovascular Intervention, Abdo-Pelvic Surgery, and Neurosurgery, among others. For more information about LifeHealthcare, please visit www.lifehealthcare.com.au or www.lifehealthcare.co.nz.
About Viscogliosi Brothers
Viscogliosi Brothers, LLC is a family-owned New York City-based family office dedicated to driving growth and innovation in the neuro-musculoskeletal industry. Established in 1999, the firm focuses on identifying and building groundbreaking innovations in healthcare, aiming to address unmet clinical needs, enhance patient outcomes, and drive cost efficiency in the healthcare system. Since its inception 26 years ago, Viscogliosi Brothers has founded, financed, operated and grown 43 businesses with operations and distribution across more than 80 countries. These businesses have positively impacted millions of patients with cutting-edge innovations in healthcare. The firm has led the transformation of the spine industry through its multiple businesses specifically including: Spine Solutions, Spine Next, Paradigm Spine, Simplify Medical, Centinel Spine, Companion Spine, Spine BioPharma and Woven Orthopedic Technologies, among others. For more information, visit www.vbllc.com.
About Viscogliosi Brothers Watermark
Viscogliosi Brothers Watermark LLC is a New York City-based holding company specializing in investing in innovation within the MedTech sector. Founded in 2022, VBW is committed to creating alternative wealth for its shareholders while enhancing humanity's well-being. With a portfolio-driven investment mandate and strategic expertise, VBW supports its invested entities through financing and manufacturing capabilities. For more information, visit www.vbwholdings.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Geek Wire
6 hours ago
- Geek Wire
Have we hit ‘Peak AI'? Microsoft, Amazon, and a pivotal week for Seattle tech
This week on the GeekWire Podcast: Microsoft soars past Wall Street expectations, briefly hitting a $4 trillion valuation, while Amazon faces sharper scrutiny over its AI strategy. We break down the contrasting earnings results, analyst reactions, and what it all means for the future of AI — and Seattle's place in it. Plus: insights from Microsoft's Mustafa Suleyman on the future of Copilot, a throwback lesson from the Zune era, and a guestbook entry that shows just how mainstream ChatGPT has become. Related stories and links Recommended listens (final segment) Subscribe to GeekWire in Apple Podcasts, Spotify, or wherever you listen.
Yahoo
8 hours ago
- Yahoo
Microsoft CEO sends a surprising message on quantum computing
Microsoft CEO sends a surprising message on quantum computing originally appeared on TheStreet. We're used to Big Tech and Microsoft () being deep in AI. But now, Microsoft just made quantum feel a whole lot less sci-fi. CEO Satya Nadella isn't pitching a pipe dream, and if you thought you'd have to wait decades, think again. On Microsoft's latest earnings call, Nadella hailed quantum as 'the next big accelerator in the cloud,' and unlike most tech hype cycles, he came with receipts. 💵💰💰💵 What we see now is bigger than a quarter; it's a total reshaping of a cloud strategy, which could completely upend the AI race. Microsoft's AI-cloud engine keeps gaining steam Microsoft's fourth-quarter FY2025 results once again blew past expectations, while underscoring the depth of its cloud-AI momentum. Revenue hit a superb $76.44 billion with earnings per share at $3.65, comfortably topping Wall Street it was Azure's 39% year-over-year growth that stole the show again, supercharged by surging AI workloads and sticky enterprise demand. Investors focused on supply and not demand as the key limiter. Microsoft flagged a coming $30 billion capex surge in expanding data center capacity, responding to the AI-driven pressure on compute availability. That massive bet is already paying dividends. Microsoft Cloud's mix continues to show off sticky migration trends, growing inference activity, and healthy adoption of AI tools like Copilot. The software, infrastructure, and services flywheel is spinning faster each quarter. Analysts took note. KeyBanc upgraded the stock to Overweight, slapping a $630 price target, citing Microsoft's robust ability to maintain double-digit top and bottom-line growth. Mizuho and Melius Research chimed in, too, hailing MSFT stock a 'must-own' as it inches closer to a $4 trillion market cap. That said, over the past year, Microsoft stock has killed it, posting a 27% bump year-to-date, compared to just a 7.8% jump in S&P 500 returns. Near-term momentum has also been impressive, with Microsoft boasting a 24% return, dwarfing broader-market gains. Consequently, it's now trading at remarkably lofty pricing multiples, at over 34 times non-GAAP earnings, roughly 8% higher than its five-year average. Similarly, it's trading at 12x forward sales, approximately 10% higher than its five-year average. Microsoft leans into quantum milestone with Atom Computing Microsoft's quarterly call wasn't simply about earnings, but signaled a major paradigm shift. CEO Nadella used the July 30 earnings call to spotlight quantum as a now-now story. "The next big accelerator in the cloud will be Quantum, and I'm excited about our progress," he said. That progress is far from being hypothetical. Nadella grounded the claim with real-world momentum: "In fact, earlier this month, we announced the world's first operational deployment of a Level 2 Quantum computer in partnership with Atom Computing."That July 2025 milestone effectively turned Microsoft's quantum initiatives from a lab curiosity into a public inflection point. He further said, "This is how we will continue to think and make investments, with decade-long arcs, while making progress every quarter.' Microsoft is building Magne, a robust neutral-atom quantum system with Atom Computing. Construction begins in fall 2025, with early workloads targeted for 2027. The effort blends Azure's cloud exploits with Atom's hardware, which is part of a bigger bet on fault-tolerant systems. Across Big Tech, quantum is heating up just like the AI arms race. Google and IBM are backing superconducting paths, and though Microsoft is chasing a different lane, the goals are converging. More News: Warren Buffett unloads $1.2 billion of this popular tech stock Wall Street firm drops bold S&P 500 call after White House trade moves Jim Cramer sounds off on tariffs, hot economy, and interest rate pressures Nadella bets that Microsoft's momentum in AI and cloud can effectively compound into quantum, and that bet just got a major signal boost. Quantum's inflection point is coming into view The quantum computing industry has been building a healthy head of steam of late. In June, Nvidia CEO Jensen Huang put it bluntly: 'There's an inflection point happening in quantum computing,' suggesting that hybrid quantum-classical systems could potentially offer real-world utility soon. Billionaire tech magnate Bill Gates is even more bullish, predicting usable breakthroughs within three to five years. On top of that, the economics are catching up to the breakthrough technology as well. McKinsey's 2025 Quantum Technology Monitor pegs the quantum ecosystem's potential at a whopping $100 billion by 2035. Similarly, Fortune Business Insights projects it could jump over $1 billion in 2024 to $12.6 billion by 2032, clocking a powerful compound annual growth rate of close to 35%. Investors aren't waiting for perfect conditions. Cathie Wood's ARK Invest is leaning into the space with its thesis: 'The only way to predict the future is to invent it.' Put simply, the framing around quantum is shifting at a breakneck CEO sends a surprising message on quantum computing first appeared on TheStreet on Aug 2, 2025 This story was originally reported by TheStreet on Aug 2, 2025, where it first appeared. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
8 hours ago
- Yahoo
Stryker lowers expected tariff impact to $175M
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. By the numbers Q2 revenue: $6 billion 11.1% increase year over year Net income: $884 million 7.2% increase year over year Stryker expects a $175 million tariff impact on earnings in 2025, a slight decrease from the $200 million the company forecast in May. Stryker joins several medical device companies that have slashed tariff expectations, with several firms, including Johnson & Johnson and Boston Scientific, cutting the expected tariff hit by as much as half. Stryker CFO Preston Wells said Thursday on an earnings call that the changes were a result of the U.S. and China agreeing to significantly reduce levies. However, Stryker did not cut its forecast by as much as other companies because the recent trade agreement with the European Union, which set a tariff rate of 15%, was more than the 10% Stryker had included in its previous model. CEO Kevin Lobo said Stryker was impacted less than other companies due to its manufacturing footprint in Europe and having less of a presence in China than other medtech companies. Raised earnings forecast Stryker raised its financial forecast for the year, now expecting organic sales growth in a range of 9.5% to 10%, from a previous range of 8.5% to 9.5%. The company also raised its expectations for adjusted earnings per share by about 20 cents. Lobo said the update was driven by continued procedural strength, including implants, and demand for capital equipment. Wells said initiatives Stryker started during the COVID-19 pandemic, such as pricing and manufacturing efficiency, have helped drive margin improvements. Robot update Stryker shared an update on planned launches for the company's robots. In March, the company unveiled its latest orthopedic robot, the Mako 4. The Food and Drug Administration cleared the new system, but Stryker has not yet rolled out the robot globally, Lobo said. The company has new hip revision and spine surgery applications that are only available on Mako 4. Stryker's shoulder surgery application is currently on its Mako 3 robot, and is in the process of migrating to the newer robot, Lobo said. Because of that, the feature is still in a limited launch until next year. Stryker reported a record quarter for Mako installations, although the company did not disclose the number of robots. The company reached a milestone of 2 million robotic procedures performed with Mako during the second quarter. Recommended Reading Stryker expects $200M tariff hit, lowers earnings forecast Sign in to access your portfolio
